The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month. For further information, contact the principal investigator listed.
Phase II
9598: A Phase II Therapeutic Trial of the Use of Dabrafenib and Trametinib in Patients with BRAF V600E Mutation Positive Lesions in Erdheim Chester Disease. National Institutes of Health; Estrada-Veras, Juvianee Ibrahim. (301) 594-2952
9653: Phase II Trial of Gemcitabine-Eribulin (GE) in Cisplatin Ineligible Patients with Advanced or Unresectable Urothelial Carcinoma of the Bladder. University of California Davis Comprehensive Cancer Center P2C; Sadeghi, Sarmad. (323) 865-0553
9880: Haploidentical Donor Natural Killer (NK) Cell Infusion with Subcutaneous Recombinant Human IL-15 (rhIL-15) in Adults with Refractory or Relapsed Acute Myelogenous Leukemia. University of Minnesota Medical Center-Fairview; Miller, Jeffrey Steven (612) 624-0123
NRG-BN001: Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation with Concomitant and Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma. NRG Oncology; Mehta, Minesh P. (410) 328-9629
NRG-HN002: A Randomized Phase II Trial for Patients with p16 Positive, Non-Smoking Associated, Locoregionally Advanced Oropharyngeal Cancer. NRG Oncology; Yom, Sue Sun (415) 353-7410
Other Phases
A151315: An Analysis of Baseline Serum NTx and BAP as Independent Predictors of Overall Survival and Risk of SREs. Alliance for Clinical Trials in Oncology; Saylor, Philip James. (617) 643-1763
ECOG-E2197F-ECOG-ICSC: Tumor MicroEnvironment of Metastasis (TMEM) and MenaCalc: Validation as Prognostic and Predictive Markers. ECOG-ACRIN Cancer Research Group; Sparano, Joseph Anthony (718) 904-2555
